Assessment | Screening | SRT with baseline ranibizumaba | Monthly reviewb (months 1–11) | Month 12 | Monthly reviewb (months 13–23) | Month 24 | Month 36 | Month 48 |
---|---|---|---|---|---|---|---|---|
Visit window: Day 0 = day of successful enrolment | Day -14 to 0 | Day 0 to 21 | ±7 days | ±7 days | ±7 days | ±7 days | ±14 days | ±14 days |
Informed consent | X | |||||||
Demographics | X | |||||||
Ophthalmic history | X | |||||||
Med. history/con meds | X | |||||||
Blood pressure | X | |||||||
ETDRS visual acuity | X | X | X | X | X | X | X | |
Intraocular pressure | X | X | X | X | X | |||
Cataract assessment | X | X | X | X | X | |||
Biometry | X | |||||||
OCT (sent to reading centre) | X | X | X | X | X | |||
OCT (not sent to reading centre) | X | X | X | |||||
Fundus photographs (sent to reading centre) | X | X | X | X | X | |||
Fluorescein angiography (sent to reading centre) | X | X | X | X | X | |||
Indocyanine green angiographyc (sent to reading centre) | X | |||||||
Stereotactic radiotherapy with mandated baseline ranibizumaba | X | |||||||
Ranibizumab injection if required (prn) | X | X | X | X | X | X | ||
Health Economics questionnaires | X | X | X | X | X | X | ||
EQ-5D and VFQ-25 patient questionnairesd | X | X | X | X | X | |||
Adverse events/ConMed changes | X | X | X | X | X | X |